Department of Physical Therapy for Internal Medicine and Geriatrics, Faculty of Physical Therapy, October University for Modern Sciences and Arts (MSA), 6th October City, Giza, Egypt.
Eur Rev Med Pharmacol Sci. 2024 Feb;28(3):1227-1233. doi: 10.26355/eurrev_202402_35361.
In chronic obstructive pulmonary disease (COPD), high-frequency chest wall oscillations (HFCWO) and lung flute (LF) are used to improve COPD patients' pulmonary functions, exertional dyspnea, as well as life quality. This comparative study aimed to assess the efficiency of HFCWO vs. LF in post-coronavirus-disease (COVID) men with COPD.
Sixty post-COVID men with COPD, who were aged 40-60 years old, were included in this HFCWO-vs.-LF comparative study and were divided into two groups. One group (N=30) received HFCWO, and the other group (N=30) received LF three times per week. Both groups' pulmonary functions, including forced vital capacity (FVC), forced expiratory volume at the first second (FEV1), the ratio of FEV1/FVC (FEV1/FVC), forced expiratory flow between 25% and 75% of the pulmonary volume (FEF25-75%) were assessed. Also, the COPD assessment test score (CAT score) and 6-minute walk distance (6MWD) were measured before and following the trial.
Regarding all variables (post-COVID patients' FVC, FEV1, FEV1/FVC, FEF25-75%, CAT score, as well as 6MWD), both groups had substantial changes after the three-week HFCWO-vs.-LF interventional period as the p-value was below 0.05. The changes in post-COVID patients' FEV1, FEV1/FVC, and 6MWD were high in the HFCWO group, while the changes in post-COVID patients' CAT score, FVC, and FEF25-75% were high in the LF group.
HFCWO is more efficient than the LF in improving pulmonary functions and exertional dyspnea in post-COVID men with COPD.
在慢性阻塞性肺疾病（COPD）中，高频胸壁振荡（HFCWO）和肺笛（LF）被用于改善 COPD 患者的肺功能、运动性呼吸困难以及生活质量。本对比研究旨在评估 HFCWO 与 LF 对新冠后 COPD 男性患者的疗效。
本 HFCWO 与 LF 对比研究纳入了 60 名年龄在 40-60 岁之间的新冠后 COPD 男性患者，他们被分为两组。一组（N=30）接受 HFCWO，另一组（N=30）接受 LF，每周 3 次。两组的肺功能（包括用力肺活量（FVC）、第 1 秒用力呼气量（FEV1）、FEV1/FVC 比值、用力呼出 25%-75%肺活量时的流量（FEF25-75%））均进行了评估。同时，在试验前后还测量了 COPD 评估测试评分（CAT 评分）和 6 分钟步行距离（6MWD）。
对于所有变量（新冠后患者的 FVC、FEV1、FEV1/FVC、FEF25-75%、CAT 评分以及 6MWD），两组在经过 3 周的 HFCWO 与 LF 干预后都有显著变化，p 值均小于 0.05。HFCWO 组的新冠后患者 FEV1、FEV1/FVC 和 6MWD 变化较大，而 LF 组的新冠后患者 CAT 评分、FVC 和 FEF25-75%变化较大。
在新冠后 COPD 男性患者中，HFCWO 在改善肺功能和运动性呼吸困难方面比 LF 更有效。
